| Schedule of Segment Financial Information |
The
following table summarizes the segment’s financial information including the Company’s significant segment expenses:
Schedule
of Segment Financial Information
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three Months Ended
June
30,
|
|
|
Six Months Ended
June 30,
|
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Research and development |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
| Clinical |
|
|
(20,676 |
) |
|
|
1,568,812 |
|
|
|
705,645 |
|
|
|
2,439,727 |
|
| Nonclinical |
|
|
166,478 |
|
|
|
91,631 |
|
|
|
311,179 |
|
|
|
212,034 |
|
| Personnel related |
|
|
472,033 |
|
|
|
348,659 |
|
|
|
882,152 |
|
|
|
958,082 |
|
| Total research and development |
|
$ |
617,835 |
|
|
$ |
2,009,102 |
|
|
$ |
1,898,976 |
|
|
$ |
3,609,843 |
|
| General and administrative |
|
|
1,154,896 |
|
|
|
874,640 |
|
|
|
2,213,559 |
|
|
|
2,477,459 |
|
| Interest income |
|
|
71,638 |
|
|
|
54,636 |
|
|
|
107,855 |
|
|
|
123,934 |
|
| Net loss |
|
$ |
(1,701,093 |
) |
|
$ |
(2,829,106 |
) |
|
$ |
(4,004,680 |
) |
|
$ |
(5,963,368 |
) |
|